| abstract |
The present invention provides a CAR-T cell that efficiently and stably expresses an activating antibody and its use. Specifically, an expression cassette containing a nucleic acid sequence encoding a chimeric antigen receptor and an activating antibody against CD28 is stably integrated into the genome of the transgenic T cell of the present invention, and both ends of the expression cassette contain transposon transposons. repeat sequence to the terminal; wherein, the chimeric antigen receptor is a chimeric antigen receptor against the EGFR family, and the activating antibody against CD28 is a membrane-anchored antibody. The pluripotent CAR-T cell genome of the present invention is stably integrated with the expression cassette of the activating antibody through the transposon system, so as to maintain the original CAR-T cell killing activity, it has the activity of stably and efficiently expressing the activating antibody , so that the reinfused cells can rapidly proliferate at the tumor site. At the same time, in order to ensure the safety of the pluripotent CAR-T cell therapy, the present invention introduces a molecular brake system, and if necessary, the reinfused pluripotent CAR-T cells can be removed in time. |